Avid Bioservices Inc (CDMO): Projects Antibody targeting of phosphat...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	86
Posts	12714
Boards Moderated	0
Alias Born	10/12/2010

biopharm

Re: biopharm post# 243289

Friday, 02/12/2016 10:54:46 PM

Friday, February 12, 2016 10:54:46 PM

Projects
Antibody targeting of phosphatidylserine produces a cytokine microenvironment that enhances innate anti-tumor immune responses(Link)
April 2008

No. 4079: Monica L. Friedrich, Claudia I. Guevara, Daniel M. Falcon,
Longen Zhou, Connie Chang and Bruce Freimark, Antibody targeting of
phosphatidylserine produces a cytokine microenvironment that enhances innate anti-tumor immune responses, Peregrine Pharmaceuticals, Inc.

This yellow sticky fell off the board and just picking it back up... it has Fujifilm Diosynth Biotechnologies on it and leads back to Steve Bagshaw CEO of Fujifilm and ex-Zeneca (what is now AstraZeneca..)

Too many familiar names here, starting with Longhen Zhou and here we go again...

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!